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Abstract
Background: A systematic review was conducted to evaluate the literature regarding the impact
of follow-up on colorectal cancer patient survival and, in a second phase, recommendations were
developed.
Methods: The MEDLINE, CANCERLIT, and Cochrane Library databases, and abstracts published
in the 1997 to 2002 proceedings of the annual meeting of the American Society of Clinical
Oncology were systematically searched for evidence. Study selection was limited to randomized
trials and meta-analyses that examined different programs of follow-up after curative resection of
colorectal cancer where five-year overall survival was reported. External review by Ontario
practitioners was obtained through a mailed survey. Final approval of the practice guideline report
was obtained from the Practice Guidelines Coordinating Committee.
Results: Six randomized trials and two published meta-analyses of follow-up were obtained. Of six
randomized trials comparing one follow-up program to a more intense program, only two
individual trials detected a statistically significant survival benefit favouring the more intense follow-
up program. Pooling of all six randomized trials demonstrated a significant improvement in survival
favouring more intense follow-up (Relative Risk Ratio 0.80 (95%CI, 0.70 to 0.91; p = 0.0008).
Although the rate of recurrence was similar in both of the follow-up groups compared,
asymptomatic recurrences and re-operations for cure of recurrences were more common in
patients with more intensive follow-up. Trials including CEA monitoring and liver imaging also had
significant results, whereas trials not including these tests did not.
Conclusion:  Follow-up programs for patients with curatively resected colorectal cancer do
improve survival. These follow-up programs include frequent visits and performance of blood CEA,
chest x-rays, liver imaging and colonoscopy, however, it is not clear which tests or frequency of
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visits is optimal. There is a suggestion that improved survival is due to diagnosis of recurrence at
an earlier, asymptomatic stage which allows for more curative resection of recurrence.
Based on this evidence and consideration of the biology of colorectal cancer and present practices,
a guideline was developed.
Patients should be made aware of the risk of disease recurrence or second bowel cancer, the 
potential benefits of follow-up and the uncertainties requiring further clinical trials. For patients at 
high-risk of recurrence (stages IIb and III) clinical assessment is recommended when symptoms 
occur or at least every 6 months the first 3 years and yearly for at least 5 years. At the time of 
those visits, patients may have blood CEA, chest x-ray and liver imaging. For patients at lower risk 
of recurrence (stages I and Ia) or those with co-morbidities impairing future surgery, only visits 
yearly or when symptoms occur. All patients should have a colonoscopy before or within 6 months 
of initial surgery, and repeated yearly if villous or tubular adenomas >1 cm are found; otherwise 
repeat every 3 to 5 years. All patients having recurrences should be assessed by a multidisciplinary 
team in a cancer centre.
Background
Colorectal cancer is one of the most common malignan-
cies with an estimated age-adjusted annual incidence in
North America of 75 cases per 100,000 population [1–3].
About 75% of newly diagnosed cases have the tumour
confined to a portion of the bowel and regional lymph
nodes. Complete removal of the tumour en-bloc with a
portion of normal bowel along with mesenteric and
regional lymph nodes is considered a curative resection.
In spite of this curative resection approximately half the
patients develop recurrent disease and their median sur-
vival does not exceed two years [1–4]. Most of these recur-
rences occur in patients who, at initial staging, had a
tumour invading across the bowel wall causing perfora-
tion of the bowel, adhesion, invasion of neighbouring
organs (stage IIb disease), or had lymph node metastases
(stage III disease). Beside disease recurrence, patients with
colorectal cancer are considered to be at a higher risk for
developing a second or metachronous bowel cancer [5–
10], particularly if they are 60 years of age or younger
[8,9].
The principal aim of follow-up programs after curative
resection of colorectal cancer is to improve survival. To
achieve this goal, patients are screened for early recurrent
disease and second colorectal cancer with the intent of a
second curative surgery. Common sites of recurrence and
the screening tests used to detect early disease in those
sites are shown in Table 1. As no single screening test is
best for all sites of recurrent disease and second colorectal
cancer, a combination or package of tests is commonly
used. The screening tests are directed to areas of potential
disease and conducted at pre-established intervals. Since
the incidence of recurrent disease occurs at an exponential
rate over the first three to four years after surgery but then
plateaus [1–3], the screening tests for recurrent disease are
conducted frequently during the first three years and infre-
quently afterwards. Screening tests for second colorectal
cancer, on the other hand, must be done at equally spaced
intervals for life because the incidence of second colorec-
tal cancer occurs at a constant cumulative rate of 3% every
six years [6,9]. An example of this strategy is noted in a
1994 survey of members of the American Society of Colon
and Rectal Surgeons [11]; it showed that most patients are
assessed every three months for three years, and every six
to twelve months thereafter. During those visits patients
have clinical assessment, blood tests including CEA (car-
cinoembryonic antigen), x-rays of the chest and abdo-
men, and colorectal endoscopy.
A debate has developed as to the effectiveness and expense
of intensive follow-up programs. A program of colorectal
cancer follow-up similar to those described by Vernava et
al [11], and using U.S. costs per test given by Nelson [12],
would have an approximate five-year cost per patient of
$10,000, half of it being due to colonoscopy. This cost
does not include surgical procedures ($8,000 per opera-
tion) for asymptomatic disease, most of which cannot be
curatively resected. Several other investigators have also
emphasized these high economic costs [13,14]. Similar
costs will occur in the Canadian context. There is also the
added potential for possible harms that may result from
such intensive follow-up programs [15–18]. This debate
has resulted from the varied and likely biased results of
non-randomized studies [19–28] and meta-analyses
based mostly on these studies [29,30]. The purpose of the
present systematic overview is to critically evaluate the
results of available randomized trials and corresponding
meta-analyses to obtain more definitive evidence regard-
ing the impact of colorectal cancer follow-up on patient
survival. Further, we investigate attitudes of Ontario phy-
sicians regarding follow-up practices to develop appropri-
ate recommendations.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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Methods
This practice guideline report was developed by the Prac-
tice Guidelines Initiative (PGI), using the methodology of
the Practice Guidelines Development Cycle [31]. The
practice guideline report is a convenient and up-to-date
source of the best available evidence on follow-up of
patients with curatively resected colorectal cancer, devel-
oped through systematic reviews, evidence synthesis, and
input from practitioners in Ontario. The report is
intended to enable evidence-based practice. The Practice
Guidelines Initiative is editorially independent of Cancer
Care Ontario and the Ontario Ministry of Health and
Long-Term Care.
Evidence was selected and reviewed by one member of the
PGI's Gastrointestinal Cancer Disease Site Group (DSG)
and methodologists. Members of the Gastrointestinal
Cancer DSG disclosed potential conflict of interest infor-
mation, reviewed the analysis of the evidence and pre-
pared draft recommendations. External review was
obtained from a random sample of a registered list of
Ontario practitioners involved in cancer patient care. The
mailed survey consisted of items that addressed the qual-
ity of the draft practice guideline report and recommenda-
tions, and whether the recommendations should serve as
a practice guideline. Final approval of the original guide-
line report modified by practitioners' feedback was
obtained from the Practice Guidelines Coordinating
Committee (PGCC).
The PGI has a formal standardized process to ensure the
currency of each guideline report. This consists of periodic
review and evaluation of the scientific literature and,
where appropriate, integration of this literature with the
original guideline information.
Examination Of The Evidence
Literature Search Strategy
MEDLINE (1966 to May 2003), CANCERLIT (1983 to
May 2003) and the Cochrane Library (2003, issue 1) were
searched with no language restrictions. "Colonic neo-
plasms" (Medical subject heading [MeSH]), "rectal neo-
plasms" (MeSH) and "colorectal neoplasms" (MeSH)
were combined with "recurrence" (MeSH), "prognosis"
(MeSH), "compliance" (MeSH), "survival analysis"
(MeSH) and the following phrases used as text words:
"follow-up" and "surveillance." These terms were then
combined with the search terms for the following study
designs or publication types: randomized controlled tri-
als, systematic reviews or meta-analyses, and clinical
guidelines. Details of the literature search strategy appear
in Appendix 3 - see Additional file: 3. In addition, investi-
gators personal files and reference lists from retrieved
papers were searched for additional trials.
Study Selection Criteria
Articles were selected for inclusion in this systematic
review of the evidence if they were fully published reports
or published abstracts of:
1. Randomized trials comparing groups of patients receiv-
ing different follow-up programs after curative resection
of colorectal cancer, and overall patient survival was
reported.
2. Meta-analyses of these randomized trials.
Excluded were non-randomized studies or randomized
trials without at least 5-year survival data.
Table 1: Sites of recurrent disease and screening tests for colorectal cancer.
Site of Recurrence Percent of Patients with Recurrence at 5 Years by Site of Initial 
Tumoura
Screening Tests
Colon Rectum
Liver 35 30 CEA, US or CT, RIS?, Sx
Lung 20 30 Chest x-ray, CEA, Sx
Peritoneal 20 20 CEA, Sx, CT, RIS?
Retroperitoneal 15 5b CEA, CT, RIS?, Sx
Peripheral Lymph Nodes 2 7b Physical exam, CEA
Other (brain, bones) <5 <5 Sx, scans
Loco-regional 15 35b CT pelvis, CEA, RIS? Sx, 
endoscopy? FOB?
Second or metachronous 
colorectal cancer
3 3 Colonoscopy, FOB?
Note: ?, questionable test; CEA, carcinoembrionic antigen; CT, computerized tomography; FOB, fecal occult blood; RIS, radioimmunoscintigraphy; 
Sx, symptoms; US, ultrasound. a Data modified from Galandiuk et al (4). The median time to recurrence is significantly shorter for stage C versus B 
and for lesions that originally had perforation or adhesion/invasion of surrounding structures (p < 0.01). b Indicates significant differences (p < 0.05).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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Although survival was the main outcome of interest,
results of trials were also searched for recurrence rates,
time to recurrence, asymptomatic recurrences, re-opera-
tion rates for recurrences, complications, and compliance
with follow-up programs.
Synthesizing the Evidence
Only published data has been used for this systematic
review. Due to the multiple factors that can affect survival
results (e.g., variety and frequency of screening tests, com-
pliance with tests and interventions, co-morbidity), both
clinical and statistical heterogeneity among study results
was expected. Prior to the estimation of risk reduction,
each study was appraised individually by two authors (AF,
BR) using the Detsky instrument [32]. Mortality rates for
both groups were assessed for heterogeneity using scatter
plots according to the methodology described by L'Abbe
et al [33], and visual impressions were confirmed by cal-
culating heterogeneity coefficients with significance levels
set at 0.10 as recommended in the statistical literature
[33,34]. Mortality rates were pooled using Review Man-
ager 4.1 (Metaview© Update Software), which is available
through the Cochrane Collaboration. The numbers used
for data pooling were those reported or those calculated
from survival rates in published data. Results were
reported as relative risk ratios (RR) with 95% confidence
intervals (CI) obtained by the random effects model of
DerSimonian and Laird [35]. An RR less than one favours
the more intense follow-up and an RR more than one
favours less intense follow-up. Inverted funnel plots were
done to investigate publication bias [34].
It was planned, a priori, to conduct a subgroup analysis to
examine the pooled results of studies using or not using
blood CEA testing and liver imaging. This was based on
the premise that these screening tests were widely used,
and was therefore considered important for analysis.
Survival rates from the randomized trials were pooled and
the results were used to develop recommendations for fol-
low-up programs.
Results
Literature Search Results
The literature search identified eight randomized trials
[36–43] and two published meta-analyses of randomized
trials [44,45]. Two of the randomized trials are excluded.
The trial by Lennon et al [42] investigated patients only
after the development of an elevated CEA determination
and, therefore, is not comparable with the other trials
where patients were randomized shortly after surgery. The
trial by Barillari et al [43] combined results of randomized
with non-randomized patients. Therefore, these two trials
are excluded from the analysis. The remaining six rand-
omized trials were classified according to the intensity of
follow-up programs compared and use of blood CEA test-
ing and liver imaging (Table 2).
Quality of trial reporting
Study evaluation with the Detsky instrument [32]
detected significant deficits in the reporting of trial design
and performance. Although all trials randomized patients
after surgery, the description of the randomization proc-
ess and stratification for prognostic factors was rarely
mentioned [39]. It was impossible to assess bias in assign-
ment except for the trial by Schoemaker et al [39]. Criteria
for patient inclusion and exclusion were described but co-
morbidity was not mentioned. Criteria to measure out-
comes were described and seemed objective but blind
assessment was mentioned in only the trial by Schoe-
maker et al [39]: radiologists unaware of follow-up assign-
ment. Except for the Schoemaker et al study [39] it is not
known how many patients were excluded from randomi-
zation due to refusal, co-morbidity or other factors. The
follow-up regimens were well described. The statistical
analysis was appropriate. Sample size justification and
confidence intervals for negative trials were mentioned in
only two trials [38,39]. Overall scores ranged from 0.57 to
0.86, median 0.67.
Compliance with the programs of follow-up were
described in three trials [37,39,41]. The description was
about drop-outs in all three and compliance with testing
in two [37,39]. Most patients were followed for five years
except one study in which reported only 52% of patients
Table 2: Classification of randomized trials of colorectal cancer follow-up
Trials [Reference] Follow-up programs 
compared
CEA testing used Liver Imaging testing used
Makela [36] Intense vs. Conventional Yes Yes
Ohlsson [37] Intense vs. Minimal Yes No
Kjeldsen [38] Intense vs. Minimal No No
Schoemaker [39] Intense vs. Minimal No* Yes
Pietra [40] Intense vs. Conventional Yes Yes
Secco [41] Intense vs. Minimal Yes Yes
* Isolated increase in CEA levels did not trigger further investigations.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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doing so [38] and another indicating only median follow-
up time [41].
Population investigated
In all randomized trials, the study population was
patients who underwent curative resection for colorectal
cancer. There were 1679 patients, with a male to female
ratio of 1.17, a median age in the mid-sixties and an age
range of 30 to 87 years; one trial had a cut-off age of 76.
Tumours involved the colon (n = 837) and rectum (n =
505). All trials included patients with Dukes' or modified
Dukes' stages A, B and C. Patients with stage Dukes' C
comprised only 33% of the populations studied. Only
one trial had a risk-adapted follow-up for patients at
higher and lower risk of recurrence [41]. Patient character-
istics were reported in tabular form and appeared compa-
rable. Formal statistical tests were rarely performed.
Outcomes
Randomized Trials
The six randomized trials [36–41] reported the survival of
patients who received different follow-up programs fol-
lowing curative surgery. Four trials compared intensive
follow-up (intervention) to minimal follow-up (control)
[and two trials compared intensive follow-up (interven-
tion) to conventional follow-up (control)] (Table 2).
Blood CEA testing was used in the management of
patients in four trials [36,37,40,41], and liver imaging was
used in four trials [36,39–41] (Table 2).
The follow-up programs for each of the trials are shown in
Table 3. Results of individual trials are presented in Table
4.
Table 3: Description of randomized trials of follow-up of colorectal cancer after resection.
Study 
[Reference]
Location 
(Years)
Follow-up Program
Control Intervention
Makela [36] Finland 
(1988–90)
Regular (n = 54): Clinical assessment, blood 
counts and CEA, chest x-ray, and fecal occult 
blood (FOB) every 3 months for 2 years, then 
every 6 months for next 3 years; rigid 
sigmoidoscopy for rectosigmoid tumours at 
each visit, and yearly barium enema for all 
patients.
Intensive (n = 52): Clinical assessment, blood counts and CEA, 
chest x-ray and FOB as in regular follow-up program. In addition, 
colonoscopy at 3 months if not performed preoperatively and then 
yearly thereafter on all patients, flexible sigmoidoscopy for 
rectosigmoid tumors every 3 months, liver ultrasound every 6 
months, and yearly CT of liver and site of operation.
Ohlsson [37] Sweden 
(1983–86)
Minimal (n = 54): FOB every 3 months for 2 
years, then yearly, and to consult for a list of 
symptoms.
Regular (n = 53): Clinical assessments, blood CEA and liver 
enzyme, chest x-ray, FOB and rigid sigmoidoscopy every 3 months 
for 2 years, then every 6 months; endoscopy control of 
anastomosis by flexible endoscopy at 9, 21, and 42 months; 
complete colonoscopy at 3, 15, 30, and 60 months; CT of pelvis (if 
they had abdominoperineal resection) at 3,6,12, 18, and 24 
months.
Kjeldsen [38] Denmark 
(1985–94)
Minimal (n = 307): Clinical assessment, blood 
hemoglobin, sedimentation rate and liver 
enzymes, chest x-ray, FOB, and colonoscopy (if 
incomplete, double contrast barium enema) at 
5, 10, and 15 years.
Regular (n = 290): Same tests as minimal follow-up program, but 
tests were conducted every 6 months for 3 years, and then at 4, 5, 
7.5, 10, 12.5, and 15 years.
Schoemaker 
[39]
Australia 
(1984–90)
Minimal (n = 158): Clinical assessment, blood 
counts, CEA, liver function tests and FOB every 
3 months for 2 years, then every 6 months for 5 
years; chest x-rays, liver CT scan and 
colonoscopy at 5 years.
Regular (n = 167): Clinical assessment, blood counts, CEA, liver 
function tests and FOB as in regular follow-up program. In 
addition, chest x-rays, liver CT scan and colonoscopy annually. 
Isolated increase in CEA levels did not trigger further 
investigations.
Pietra [40] Italy 
(1987–90)
Regular (n = 103) Clinical assessment, CEA, and 
liver ultrasound every 6 months for one year, 
then yearly; chest x-ray and colonoscopy yearly.
Intensive (n = 104) Clinical assessment, CEA, and liver ultrasound 
as regular follow-up program, but tests conducted every 3 months 
for 2 years, then every 6 months for 3 years, and yearly thereafter. 
In addition, chest x-ray, abdominal CT and colonoscopy yearly.
Secco [41] Italy 
(1988–96)
Minimal (n = 145) Patients to phone the surgical 
team every 6 months. Clinical assessment by 
family physician at least once a year or when 
suggestive symptoms of recurrence occurred.
Intensive (n= 192) High Risk Patients: Clinical assessment and CEA 
every 3 months for 2 years, every 4 months in the third year and 
every 6 months in years 4 and 5. Abdominal and pelvic ultrasound 
performed every 6 months the first 3 years and yearly in years 4 
and 5. Rigid recto-sigmoidoscopy and chest x-ray yearly for 
patients with rectal cancer. Low Risk Patients: Clinical assessment 
and CEA every 6 months for 2 years, then yearly; abdominal and 
pelvic ultrasound every 6 months for 2 years, then once a year. 
Rigid recto-sigmoidoscopy for rectal cancer yearly twice, then 
every 2 years and chest x-ray yearly.
Note: CEA, carcinoembryonic antigen; FOB, fecal occult blood; CT, computerized tomography.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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Overall survival is significantly improved for patients in
the more intensive programs of follow-up. This improve-
ment amounts to a risk difference of 7% (95%CI, 3% to
12%; p = 0.002) in five year survival. The number of all
recurrences was similar in programs of more and less
intense follow. The incidence of asymptomatic recur-
rences was, however, significantly more common on
patients on the more intense follow-up. The latter may
explain the more common re-operation for cure of recur-
rences in the group of patients undergoing the more
intense follow-up.
Overall survival was also investigated for the group of tri-
als according to the use of CEA and liver imaging screen-
ing. Trials using blood CEA screening demonstrate a
significant impact on survival whereas those not using
CEA do not (Figure 2). A similar finding is that whereas
trials using liver imaging show a significant improvement
in survival, and trials not using liver imaging do not (Fig-
ure 3).
Pooled results of all randomized trials revealed no statis-
tically significant heterogeneity (X2 = 3.95; p > 0.10).
Table 4: Results of randomized trials of follow-up after resection of colorectal cancer.
Study, Year 
[Reference]
Follow-up 
Program 
intensity
Number of 
Patients 
Randomized
Median 
Observation 
(months)
Overall 
Recurrence 
Rate (%)
Number of 
Second Bowel 
Cancers
Radical 
Reoperation 
Rate (%)
5-year 
Survival Rate 
(%)
Makela
1995
[36]
Less
More
54
52
>60 39
42
NR 14
23
54
59
Ohlsson
1995
[37]
Less
More
54
53
82 33
32
NR 17
29
67
75
Kjeldsen
1997
[38]
Less
More
307
290
>60 26
26
3
7
NR 68
70
Schoemaker
1998
[39]
Less
More
158
167
>60 NR 5
3
NR 70
76
Pietra
1998
[40]
Less
More
103
104
>60 19
25a
1
0
10
65
58
73b
Secco
2002
[41]
Less
More
145
192
>60 53
57
NR 16
31
48
63
Note: NR, not reported. a p < 0.01 b p < 0.05
Pooled results of randomized trials: overall mortality at five years Figure 1
Pooled results of randomized trials: overall mortality at five years. Overall relative risk ratio = 0.80 (95% CI, 0.70 to 
0.91; p = 0.0008)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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There was no evidence of publication bias as the relative
risk ratios of the individual trials distributed symmetri-
cally about the pooled risk ratio.
Meta-analyses
Two meta-analyses of randomized trials have been pub-
lished [44,45]. Both studies are of excellent methodologi-
cal quality with clear description of bibliographical
search, inclusion/exclusion criteria, standardized collec-
Pooled results of randomized trials: overall survival sub-group analysis. [No CEA testing; CEA testing] Figure 2
Pooled results of randomized trials: overall survival sub-group analysis. [No CEA testing; CEA testing]. Overall 
relative risk ratio, no CEA testing = 0.90 (95% CI, 0.73 to 1.09; p = 0.28)Overall relative risk ratio, CEA testing = 0.71 (95% CI, 
0.60 to 0.85; p = 0.0002)
Pooled results of randomized trials: overall survival sub-group analysis. [No liver imaging; liver imaging] Figure 3
Pooled results of randomized trials: overall survival sub-group analysis. [No liver imaging; liver imaging] Over-
all relative risk ratio, no liver imaging = 0.91 (95%CI, 0.73 to 1.14; p = 0.40)Overall relative risk ratio, liver imaging = 0.74 
(95%CI, 0.63 to 0.87; p = 0.0004)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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tion of data, consideration of quality of trial reporting,
concerns with possibility of biases in publication and
reporting, and high level statistical management of the
data. In both studies, further details not reported in the
published trials were obtained by contacting investigators
involved with the trials; however, which data was
acquired in this manner is not reported.
Both studies analyzed the same five randomized trials
[36–40]. The analysis by Renehan et al [44] found a signif-
icant improvement in overall survival, with a larger effect
in four trials using abdominal CT scans and frequent CEA
determinations. In attempting to explain the survival ben-
efits, the authors note the similar recurrence rates regard-
less of follow-up plan but the earlier diagnosis (by 8.5
months; 95% CI; 7.6 to 9.4) and the more frequent find-
ing of isolated local recurrences with the more intense fol-
low-up. The study by Jeffery et al [45] had similar
findings: improved survival, no difference in recurrence
rates, earlier diagnosis of recurrences and more frequent
curative resection on patients undergoing more intense
follow-up. Further, this occurred because of performing
more tests, especially liver imaging. These latter results,
when expressed as risk differences, were not significant.
Both studies noted the low rate of metachronous cancer,
which was not different for the compared follow-up pro-
grams. Also noted in these overviews are the paucity of
data on complications and quality of life: colonoscopy
complication rate by Schoemaker et al [39] and the lim-
ited quality of life study by Kjeldsen et al [46]. The conclu-
sions of these systematic reviews are that intensifying
programs of follow-up improve survival but that there is
no data to recommend tests or frequency of visits.
Discussion
We must start by acknowledging that results of only two
individual studies [40,41] showed a statistically signifi-
cant benefit in survival for organized programs of follow-
up of patients with curatively resected colorectal cancer.
However, some of these studies [36,37] lacked the power
to detect statistically significant differences in survival
associated with two follow-up programs of different
intensities. Meta-analysis, by pooling the results of under-
powered studies, may detect small but clinically signifi-
cant differences. Indeed, meta-analyses by Renehan et al
[44] and Jeffery et al [45] have shown significant improve-
ments in survival for patients on more intense follow-up.
The results obtained in our pooled analysis of the six ran-
domized trials comparing two intensities of follow-up
also demonstrated that patients on more intensive pro-
grams of follow-up have improved survival compared
with patients on minimal or no follow-up (Relative Risk
Ratio 0.80 (95% CI; 0.70 to 0.91; p = 0.0008).
The finding of decreased mortality with more intensive
follow-up does not permit us to recommend a specific
program of follow-up. To be more specific, we
investigated the role of CEA monitoring and use of liver
imaging. Our results demonstrate that only trials
including CEA testing and/or liver imaging give signifi-
cant improvements in survival (Figure 2 and 3). It must be
stressed that all studies including liver imaging also used
blood CEA monitoring. CEA testing alone was investi-
gated in a randomized trial by Lennon et al [42] but
unfortunately other screening tests were not controlled.
Patients were randomized only after a period of follow-up
and when the CEA level was significantly elevated over
several weeks and then to either an aggressive surgical
approach to search and resect recurrence or a more con-
ventional approach. Preliminary results indicate no differ-
ence in post-randomization survival. The lack of survival
benefit of an aggressive surgical approach to CEA eleva-
tion may be due to several causes: 1) More than 60% of
patients with elevated CEA had symptoms suggestive of
disease. 2) There was no control for other tests which may
render the CEA screening ineffective. 3) The criteria for
CEA elevation required two values over 20 ng/ml or two
values over 10 ng/ml but with a rise of greater than seven
units. This conservative estimate of elevated CEA will
decrease the diagnostic sensitivity of the test and may
delay the diagnosis by two or three months, which may
have an impact on patient survival. 4) This trial required
an "aggressive" pursuit of the diagnosis of recurrent dis-
ease that might include a second-look laparotomy. This
"aggressive" approach may cause some harm, reducing
the benefit of CEA monitoring. Therefore, the negative
results of this trial do not negate a potential benefit for
CEA testing. Our finding of a CEA effect may simply rep-
resent confounding factors. CEA testing has been com-
bined with chest and abdominal imaging and endoscopic
examination. These factors as well as CEA testing may
have an impact on survival results.
In regard to liver imaging, three studies used computer-
ized tomography (CT) [36,39,40] while one study used
ultrasonography (US) [41]. Computerized tomography
has been shown to be more sensitive than US in detecting
liver metastases [47,48]. In a cohort study of 100 patients
with resected colorectal cancer (mostly Dukes' stage C)
who had normal livers as determined by CT, US, and
intra-operative palpation of the liver [49], several imaging
tests and CEA were performed after a median follow-up of
41 months (range 36 to 48). Sensitivity for the detection
o f  l i v er  m e t a st a s e s  wa s :  f o r  C T  0 . 67  ( 9 5%  C I ;  0 . 4 3  to
0.91), for US 0.43 (95% CI; 0.17 to 0.69), and for CEA
0.33 (95% CI; 0.09 to 0.57). The addition of CEA to CT
and US increased the sensitivity up to 0.53 and 0.73,
respectively. This study did not address the question ofBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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whether detection of resectable liver lesions was better by
any of the screening methods.
Imaging of the chest by plain radiographs has been
included in all intensive follow-up programs. Lung metas-
tases occur in 25% of patients with resected colorectal
cancer (Table 1); localized lesions are less common but
resection led to 30% long-term survival [50]. In a large
cohort study of 1247 patients with resected colon cancer
[51], recurrences occurred in 548 after a median follow-up
of 7 years. There were 22 patients with resectable lung
metastases, all detected by plain chest radiographs, and 6
were long-term survivors. In the same study, only 49
patients had hepatic resections and 32% survived more
than 5 years. Thus, although plain radiographs detect very
few patients with localized lung metastases, the situation
is very similar to that of liver metastases. Computerized
tomography of the chest has not been used as a screening
test in colorectal cancer.
In regard to the incidence of second bowel cancer, no def-
inite comments can be made based on the evidence
reviewed. Only three randomized trials reported on the
incidence of such tumors and the rates were similar for
both follow-ups. Most studies had median observation
periods around five years. Therefore, the expected number
of metachronous cancers in these patients is <3% [6,7].
Patient compliance with the follow-up plans is described
in three trials [37,39,41]. Overall, it appears that patients
are quite willing to undergo frequent visits and tests.
The improvement in patient survival receiving intensive
follow-up programs is achieved at the cost of frequent vis-
its, extensive testing, earlier knowledge of disease recur-
rence, and increased number of further testing and
surgical interventions. Harmful consequences of such
extra testing and intervention have rarely been measured
in randomized trials. One trial noted two perforations
and two episodes of bleeding after polypectomy in 731
colonoscopies, a complication rate of 0.55% [39]. This
complication rate is comparable to that of other colonos-
copy series [52]. The quality of life and attitudes of
patients participating in follow-up programs were initially
investigated in a pilot study by Stiggelbout et al [53].
Results indicated that regular contact with a physician
reassured patients and that visits and tests caused only
slight anticipatory anxiety and other minor inconven-
iences. Kjeldsen et al [46] confirmed these findings in a
subgroup of patients participating in a randomized trial
comparing minimal to regular follow-up and which dem-
onstrated similar survival for both follow-ups [38]. Qual-
ity of life (Nottingham Health Profiles) and patient
attitudes toward follow-up were investigated on 350 of
597 patients who were alive after closure of the rand-
omized trial. Patients were mailed the questionnaires to
complete at home. Ninety-one percent of patients
returned completed questionnaires. Quality of life meas-
ures and attitudes were almost the same for patients on
the minimal and intensive follow-up indicating the extra
tests or inconveniences were balanced by the more fre-
quent reassurance of health. These results are also consist-
ent with those of one of the randomized trials in resected
breast cancer follow-up where there was no impact of fol-
low-up on the patients' quality of life, even after knowing
that the follow-up program had not improved their sur-
vival [54].
In summary, follow-up programs for patients with cura-
tively resected colorectal cancer do improve survival.
These follow-up programs include frequent visits and per-
formance of blood CEA, chest x-rays, liver imaging and
colonoscopy. It is not clear which tests or frequency of vis-
its is optimal. There is a suggestion that improved survival
is due to diagnosis of recurrence at an early and asympto-
matic stage which allows for more curative resection of
recurrence. There is almost no data on complications
from testing and therapies. Patients' quality of life does
not appear to be affected.
Development Of The Clinical Practice Guideline
Gastrointestinal Cancer Disease Site Group Consensus
Intense debate occurred during several sessions around
the interpretation of the presented evidence as well as the
consideration of common practices and our role in guid-
ing other physicians as to what is an acceptable follow-up
program. Further, there are other goals for follow-up than
to increase survival, including psychosocial support, doc-
umentation of disease course and close contact with
patients to test new therapies. The evidence presented
clearly demonstrates a survival benefit for patients receiv-
ing programs of more intense follow-up. The evidence for
the schedule of visits and screening tests to detect disease
recurrence is soft or non-existent. The evidence for the use
of colonoscopy to detect second colorectal cancer and its
precursors must derive from other investigations such as
the Polyp Surveillance Study in the United States [55].
Common practice has been to follow patients at high risk
of recurrence (stages IIb and III) with clinical assessment
and blood tests including CEA every three to four months
for the first two or three years, and every six to 12 months
to complete five years following resection. Blood CEA
monitoring seems to uncover resectable liver metastases,
is relatively inexpensive and causes minimal inconven-
ience. Patients also have colonoscopy in the perioperative
period, and if adenomatous polyps are present, colonos-
copy is repeated yearly or, if no polyps are detected, every
three to five years. This practice was recommended in a
document prepared by the Gastrointestinal Cancer DSG
in January 1997 (see Appendix 2 - see Additional file: 2)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
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and a group of experts of the American Society of Clinical
Oncology recently supported similar views [56]. These
recommendations encompass the available evidence from
clinical trials and what is known about the clinical biology
of colorectal cancer recurrences and second tumours, and
should serve as a guide to other physicians. These recom-
mendations and the reviewed evidence were distributed
to Ontario physicians caring for patients with colorectal
cancer. The Gastrointestinal Cancer DSG also emphasized
that further trials are needed to determine which tests lead
to the detection of resectable recurrent disease and
whether patients' quality of life is also improved.
External Review
Practitioner feedback was obtained through a mailed sur-
vey. The survey consisted of items evaluating the methods,
results, and interpretive summary used to inform the draft
recommendations and whether the draft recommenda-
tions should be approved as a practice guideline. Written
comments were invited. Follow-up reminders were sent at
two weeks (post card) and four weeks (complete package
mailed again). The Gastrointestinal Cancer DSG reviewed
the results of the survey.
1. Number surveyed: 153 practitioners in Ontario
involved in the care of patients with cancer (9 medical
oncologists, 20 radiation oncologists, and 104 surgeons).
2. Return rate: 62%
3. Written comments attached: 44%
4. Agreement with the summary of evidence: 88%
5. Agreement with the recommendation: 76%
6. Approval of the recommendation as a practice guide-
line: 73%
Summary of Main Findings
Written comments provided by practitioners varied. One
practitioner believed that liver and lung imaging should
be included in the recommendations, since the only pos-
itive study included liver ultrasound. Another practitioner
thought that the lack of specificity of CEA testing, its cost,
and the poor results with resection of intraperitoneal
recurrences argued against its routine use. Based on the
studies that were reviewed, it is not clear how CEA testing
every four months was recommended, and this practi-
tioner suggested adding the following recommendation:
"If a patient would not be considered fit for resection of
liver, lung, or intraperitoneal metastases, there is no value
to CEA monitoring." Another practitioner thought that
clinical exam every four months would not be effective as
no resectable disease can be diagnosed on exam. Another
practitioner thought that if several randomized controlled
studies showed survival benefits for yearly colonoscopy
on an intensive follow-up program, then routine annual
colonoscopy should be recommended as suggested by the
literature review, but that the lack of evidence for the
schedule of visits should be emphasized.
Gastrointestinal Cancer Disease Site Group Modifications and 
Actions
Although 80% of the respondents were favourable to the
draft recommendations, 20% were not in full agreement
and wrote specific comments. Major concerns were low
sensitivity of clinical assessment and blood CEA, and the
more specific value in detecting resectable solitary metas-
tases by liver and chest imaging. These concerns are
reflected in a recent survey of Canadian oncologists
regarding frequency of visits and tests performed in the
follow-up of curatively resected colorectal cancer: Of
oncologists surveyed, 35% recommend liver ultrasound
and 50% recommend chest x-rays (Grunfeld et al, unpub-
lished results). In the randomized trials reviewed, the
more intensive follow-up programs which showed an
increase in survival did indeed use liver and chest imag-
ing. Therefore, we suggested the use of chest radiographs
and liver imaging with CT or US. Although CT is more
sensitive than US, availability and cost of CT are signifi-
cant problems. Similarly, modifications were made to
address the importance of an optimal decision regarding
treatment of disease recurrence. In regard to colonoscopy,
we advise the recent American Gastroenterology Associa-
tion Guidelines recommendations [57]. Other comments
were also considered, including colonoscopy for patients
with stage I disease and more intense follow-up of
patients who are fit and willing to undergo investigations
and potential intervention for recurrence, regardless of
age. An Information Sheet to be given to the patient at the
start of the follow-up (Appendix 1 - see Additional file: 1)
was added.
Several recent practice guidelines for surveillance after
colorectal cancer resection were reviewed [58–61]. Two of
these practice guidelines discussed levels of evidence for
the recommendations [58,59] but only one or two of the
RCTs analyzed in this paper were considered. The recom-
mendations are not consistent between practice guide-
lines, partly because of the use of biased data from cohort
and non-randomized studies. Clearly, even after consider-
ing only randomized studies neither of the overviews pro-
vided definite answers to the tests required, and further
research with support from sources other than those ded-
icated to patient care is required [12,18,47].
Patients should be made aware of the importance of these
research trials, and should be encouraged to participate in
them. These clinical studies should be randomized to pre-BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
Page 11 of 13
(page number not for citation purposes)
vent biases and should be directed to homogeneous
groups of patients stratified according to risks. Patients
should be randomized to specific screening procedures
(i.e., abdominal ultrasound or CT, PET scanning), and
should measure quality of life and survival. Sufficiently
long observation periods will be important to achieve reli-
able differential rates of risk, and sufficiently large sample
sizes are necessary to obtain conclusive results. In plan-
ning such trials, a cost-benefit analysis must be performed
to assess the economic costs of potential improvements in
survival and quality of life [13,14,48]. Several such trials
are under way [44,62].
Conclusions
Practice Guideline
This practice guideline applies to adult patients with cura-
tively resected colorectal cancer, defined as patients who
have had all apparent disease removed by surgery.
• Patients should be alerted to the future risks of disease
recurrence, which is related to tumour stage, and to the
development of a second colorectal cancer.
• There is evidence from six randomized trials and two
meta-analyses of a small but significant survival benefit
with more intensive follow-up compared to less intensive
follow-up. This benefit is due to the early diagnosis and
resection of limited recurrent disease in the liver, lungs, or
local sites. It seems that this diagnosis of resectable recur-
rences is due to early assessment of symptoms and the use
of screening tests (blood carcinoembryonic antigen, chest
x-ray, liver imaging, or colonoscopy). There is insufficient
evidence on which to base a recommendation for specific
screening tests and frequency of visits.
• In light of the uncertainty of the schedule of visits and
screening tests to be recommended, and based on the rate
of recurrent disease and second neoplasms and on current
practices, we advise:
1. In patients who are at high risk of relapse (stages IIb and
III disease) and are fit and willing to undergo investiga-
tions and treatment of recurrence:
- Prompt assessment for symptoms of potential disease
relapse (see Appendix 1);
- Clinical assessment at least every six months for three
years, and then annually for an additional three years;
- During those visits patients may have blood CEA, chest
x-rays, and liver ultrasound or CT;
- When recurrences of disease are detected, patients
should be assessed by a multi-disciplinary oncology team
including surgical, radiation, and medical oncologists to
determine the best treatment options.
2. In patients at high risk of relapse but who have co-mor-
bidities which may interfere with prescribed tests or
potential treatment for recurrence, or who are unwilling
to undergo prescribed tests or potential treatment for
recurrence:
- Clinical assessments yearly or for suggestive symptoms
of relapse.
3. In all patients with resected colorectal cancer (stages I,
II, and III) and based on the American Gastroenterologi-
cal Association recent guideline:
Colonoscopy postoperatively if not yet done;
- if high-risk polyps (villous or tubular >1 cm) are present,
excise as they are potential precursors of colorectal cancer;
and repeat colonoscopy yearly as long as polyps are
found.
- If there are low-risk or no polyps, repeat colonoscopy in
three to five years.
4. Patients should be encouraged to participate in clinical
trials investigating screening tests added on to their clini-
cal assessment. These trials of follow-up need to target
patients with resectable recurrent disease and who are fit
for required surgery.
List of abbreviations
In order of appearance:
CEA, carcinoembryonic antigen; PGI, Practice Guidelines
Initiative; DSG, Disease Site Group; PGCC, Practice
Guidelines Coordinating Committee; MeSH, medical
subject heading; RR, relative risk ratio; CI, confidence
interval; CT, computerized tomography; PET, positron
emission tomography.
Competing interests
None declared.
Authors' contributions
AF performed the original evidence review, participated in
the statistical analysis, and participated in the writing of
all drafts and the final version of the manuscript. BR, LZ,
and CZ participated in the statistical analysis, writing of
drafts, and providing review and commentary. Final edit-
ing and preparation of the manuscript was performed by
BR and AF. Along with AF, JM, CE, BC, and RM made up
a team of experts that determined the scope, content, and
interpretation of this systematic review.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/26
Page 12 of 13
(page number not for citation purposes)
Note
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